Key Highlights

  • Third quarter Revenue rose 9.9% to USD 393.1 million, ahead of the USD 381.1 million estimate.
  • Adjusted EPS of USD 1.23 compares with a USD 1.06 estimate, while GAAP EPS fell to USD 0.11.
  • Cardiopulmonary revenue grew 10.9% and neuromodulation revenue grew 11.1%, both delivering gains across every region.
  • Guidance now calls for 9% to 10% constant-currency revenue growth and adjusted EPS of USD 4.40 to USD 4.50.

LivaNova (NASDAQ:LIVN) reported third quarter revenue of USD 393.1 million, up 9.9% on a reported basis and 10.0% at constant currency from USD 357.8 million a year earlier. Revenue topped the USD 381.1 million estimate. Adjusted diluted EPS of USD 1.23 exceeded the USD 1.06 estimate and compares with USD 1.11 in the year-earlier quarter. GAAP diluted EPS was USD 0.11, down from USD 0.49.

Segment Growth

Cardiopulmonary revenue rose 10.9% to USD 225.3 million, with growth in every region. Management cited strong consumables demand, sales of the Essenz perfusion system and favorable realized price. Neuromodulation revenue increased 11.1% to USD 166.1 million on higher Volume and price. Other revenue fell to USD 1.7 million from USD 5.0 million, which had included a USD 3.1 million reserve reduction a year ago.

Chief executive Vladimir Makatsaria said the team delivered robust growth on commercial execution and healthy global demand, and that the updated guidance reflects confidence across the portfolio. The company also brought a dedicated oxygenator Manufacturing line into production, a step aimed at expanding capacity against strong customer demand.

In October, the American Medical Association's CPT Editorial Panel established new Category I codes that include LivaNova's proximal hypoglossal nerve stimulation therapy for moderate to severe obstructive sleep apnea, with an effective date of January 1, 2028. The company also published 36-month results from the CORE-VNS study of VNS Therapy in drug-resistant epilepsy, which showed a 76% median reduction in seizure frequency.

Profitability and Cash

GAAP Operating Income was USD 28.4 million, compared with USD 54.0 million a year ago, as other Operating Expense rose to USD 34.0 million from USD 3.7 million. GAAP Net Income was USD 34.3 million. Adjusted operating income climbed to USD 92.3 million from USD 80.4 million, a 23.5% Margin versus 22.5%, and adjusted net income was USD 70.7 million.

Selling, general and administrative expense was USD 154.9 million, or 39.4% of revenue, and Research and Development was USD 47.7 million, or 12.1%. Adjusted gross margin was 69.3%, against 69.4% a year earlier.

Net cash from Operating Activities was USD 73.7 million, and adjusted free Cash Flow was USD 55.8 million. Cash and cash equivalents stood at USD 563.5 million, compared with USD 635.6 million in the prior balance sheet. For the first nine months, revenue was USD 1.146 billion, up from USD 1.027 billion, and adjusted diluted EPS was USD 3.48 versus USD 3.04.

Raised 2026 Guidance

Management lifted its full year constant-currency revenue growth range by 100 basis points to 9% to 10%, from 8% to 9%. Currency is projected as a tailwind of about 1%, unchanged from prior guidance. Adjusted diluted EPS guidance rose to USD 4.40 to USD 4.50 from USD 4.30 to USD 4.40, based on about 56 million shares. Adjusted free cash flow guidance of USD 140 million to USD 160 million was maintained.

Balance Sheet and Cash Markers

Cash of USD 563.5 million compares with USD 635.6 million in the prior balance sheet, while third quarter Operating Cash Flow of USD 73.7 million compares with adjusted free cash flow of USD 55.8 million. Nine month adjusted EPS of USD 3.48 compares with the full year range of USD 4.40 to USD 4.50, which by simple subtraction leaves USD 0.92 to USD 1.02 for the fourth quarter. The third quarter's USD 1.23 compares with that remainder.